In early February, President Biden proposed allowing the government to “march in” and seize the patents of drugs and other innovations if drug prices are too high.
CAHC’s Joel White examines the damaging impact the use of march-in rights would have on healthcare research and innovation in a new op-ed for RealClear Health.